预约演示
更新于：2026-02-03
Lanthanum carbonate
碳酸镧
更新于：2026-02-03
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2004-10-26), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式CH4LaO4 |
InChIKeyLIOPFGUJULMLEN-UHFFFAOYSA-N |
CAS号54451-24-0 |
关联
69
项与 碳酸镧 相关的临床试验EUCTR2019-003698-24-NL
Patient preference-based phosphate binder therapy in haemodialysis patients: a feasibility study on patient satisfaction
NCT04440696
To Evaluate the Tolerance, pd, and pk of Lanthanum Polystyrene-sulfonate Powder in a Phase Ib/ IIa Clinical Trial in Patients With ESRD-HD Hyperphosphatemia With Multi-center, Multi-dose, Give the Drug Multiple Time
NCT03451019
Effect of Lanthanum Carbonate and Sevelamer Hydrochloride on Gastrointestinal Calcium Absorption in Patients With Moderate to Advanced Chronic Kidney Disease
100 项与 碳酸镧 相关的临床结果
登录后查看更多信息
100 项与 碳酸镧 相关的转化医学
登录后查看更多信息
100 项与 碳酸镧 相关的专利（医药）
登录后查看更多信息
1,105
项与 碳酸镧 相关的文献（医药）2026-01-01JOURNAL OF HAZARDOUS MATERIALS
Effect of lanthanum on microalgal ammonia removal and biomass valorization in mining wastewater: Toxicity threshold and resource recovery
Article
作者: Wang, Lan ; Shu, Jiahao ; Ikhlaq, Faizan ; Xie, Tonghui ; Xiang, Yuanpeng ; Qasim, Qasim ; Zhang, Yongkui ; Ali, Ahmad
Rare earth mining wastewater often contains both high ammonium nitrogen and residual lanthanum (La), yet how La simultaneously influences microalgal nitrogen assimilation, physiology, and biomass quality remains insufficiently resolved. This study aimed to determine how different La concentrations (0-1000 mg L⁻¹) affect the growth, metabolic responses, and ammonium-removal performance of Chlorella sorokiniana cultivated in simulated high-strength wastewater (1060 mg L⁻¹ NH₄⁺-N). The objective was achieved by integrating physiological measurements with chemical speciation modelling and transcriptomic analysis. Our results showed that a low dose of La (10 mg L⁻¹) enhanced biomass production (6.17 g L⁻¹) and accelerated NH₄⁺ removal (20.2 mg L⁻¹ d⁻¹) by upregulating the GS-GOGAT nitrogen assimilation pathway and associated carbon-fixation and energy-generation genes. Intermediate La levels (100-250 mg L⁻¹) altered cellular carbon allocation, increasing lipid accumulation (up to 31.4 % of dry weight) while gradually suppressing growth. High La concentrations (≥500 mg L⁻¹) caused pronounced toxicity, including rapid pH decline, photosynthetic inhibition, oxidative stress, and the formation of La-containing precipitates, leading to metabolic arrest and biomass collapse. SEM-EDS analysis and Visual MINTEQ modelling confirmed that both ionic La³ ⁺ and particulate La phases contributed to these inhibitory effects. This study clarifies how La regulates nitrogen assimilation, metabolism, and cellular physiology in Chlorella sorokiniana under high-ammonia conditions, providing mechanistic insight into the dual opportunities and limitations of using Chlorella in rare-earth-containing wastewaters.
2026-01-01INTERNAL MEDICINE
Association between Phosphate Binders and Constipation in Patients Undergoing Chronic Hemodialysis: A Cross-sectional Study
Article
作者: Morozumi, Kunio ; Takahashi, Hiroshi ; Kondo, Chika ; Hori, Mayuko ; Takeda, Asami ; Maruyama, Shoichi
Objective Constipation, a clinical form of gut dysbiosis, is highly prevalent in patients undergoing hemodialysis. Patients with chronic kidney disease experience uremia-related changes in the gut environment. Dysbiosis reportedly leads to an atherosclerosis pathogenesis, and constipation is associated with several adverse clinical outcomes including cardiovascular disease and mortality. Phosphate binders, commonly prescribed to patients with end-stage renal disease, bind to non-phosphate molecules and may alter the gut microbiota, potentially leading to systemic effects unrelated to phosphate control, although the clinical evidence is limited. Methods This cross-sectional study included 293 outpatients undergoing hemodialysis at Masuko Memorial Hospital, Japan. Information about patient characteristics and medication usage was collected, and constipation was assessed using the original diagnostic criteria, incorporating both the Rome IV criteria and a history of laxative use. Results Of 293 participants, 152 (51.9%) were diagnosed with constipation and 60 (20.5%) had severe constipation. Lanthanum carbonate use was independently associated with a lower risk of constipation (adjusted odds ratio [aOR] 0.55, 95% confidence interval [CI] 0.32-0.94, p=0.029) and a lower risk of severe constipation (aOR 0.41, 95%CI 0.19-0.86; p=0.018), while precipitated calcium carbonate use was associated with a lower risk of severe constipation, independent of age and sex (aOR 0.48, 95%CI 0.26-0.89, p=0.021). Conclusion Our study highlights the association between specific phosphate binders and a lower risk of constipation. Accordingly, phosphate binders could be selected based on their positive effects on constipation in this patient population.
2025-12-01INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY
Crystal-Storing Histiocytosis of the Duodenum in a Patient With IgG-Lambda Multiple Myeloma
Article
作者: Alipour, Zahra ; Yang, Zhaohai ; Koga, Shunsuke
Crystal-storing histiocytosis is a rare condition characterized by the accumulation of crystalline immunoglobulins within histiocytes, often associated with plasma cell disorders such as multiple myeloma. We report a 70-year-old man with a history of IgG-lambda multiple myeloma, systemic amyloidosis, and end-stage renal disease managed with peritoneal dialysis and long-term lanthanum carbonate therapy for hyperphosphatemia, who presented with gastrointestinal bleeding. Endoscopy revealed nodular erythematous mucosa in the duodenum, and biopsies showed histiocytosis in the lamina propria. The histiocytes showed abundant cytoplasm containing periodic acid–Schiff-positive diastase-resistant intracellular material. Immunohistochemical staining revealed diffuse CD68 positivity and lambda light-chain restriction of the storage material in the histiocytes, supporting a diagnosis of crystal-storing histiocytosis. Differential diagnoses, including Whipple disease, mycobacterial infections, lanthanum deposition, amyloidosis, and xanthoma, were excluded based on histological findings and clinical history. This report highlights the importance of recognizing crystal-storing histiocytosis in uncommon sites such as the duodenum, especially in the context of plasma cell dyscrasias.
100 项与 碳酸镧 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高磷血症 | 奥地利 | 2005-03-01 | |
| 高磷血症 | 比利时 | 2005-03-01 | |
| 高磷血症 | 保加利亚 | 2005-03-01 | |
| 高磷血症 | 丹麦 | 2005-03-01 | |
| 高磷血症 | 爱沙尼亚 | 2005-03-01 | |
| 高磷血症 | 芬兰 | 2005-03-01 | |
| 高磷血症 | 法国 | 2005-03-01 | |
| 高磷血症 | 匈牙利 | 2005-03-01 | |
| 高磷血症 | 冰岛 | 2005-03-01 | |
| 高磷血症 | 爱尔兰 | 2005-03-01 | |
| 高磷血症 | 意大利 | 2005-03-01 | |
| 高磷血症 | 拉脱维亚 | 2005-03-01 | |
| 高磷血症 | 立陶宛 | 2005-03-01 | |
| 高磷血症 | 卢森堡 | 2005-03-01 | |
| 高磷血症 | 马耳他 | 2005-03-01 | |
| 高磷血症 | 荷兰 | 2005-03-01 | |
| 高磷血症 | 挪威 | 2005-03-01 | |
| 高磷血症 | 斯洛伐克 | 2005-03-01 | |
| 高磷血症 | 斯洛文尼亚 | 2005-03-01 | |
| 高磷血症 | 西班牙 | 2005-03-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 慢性肾病 serum phosphorus | oxidative stress | vascular dysfunction | 54 | 醖顧獵構廠繭選鑰遞網(獵糧齋餘鹽齋窪鏇襯鹹) = 範製衊製糧蓋廠築遞觸 襯齋廠顧艱製淵製顧選 (選製觸糧鑰衊簾壓窪鬱 ) | 不佳 | 2024-05-23 | ||
Placebo | 醖顧獵構廠繭選鑰遞網(獵糧齋餘鹽齋窪鏇襯鹹) = 膚構艱構醖網窪衊蓋構 襯齋廠顧艱製淵製顧選 (選製觸糧鑰衊簾壓窪鬱 ) | ||||||
临床2期 | 慢性肾病 interleukin-6 | C-reactive protein | 127 | 鑰築鑰鑰製獵憲鏇鑰鏇(簾獵淵網憲選齋壓範壓) = 範艱鏇遞膚顧淵簾築窪 願製築選遞積壓窪簾餘 (餘積網積築顧糧淵鹹襯 ) 更多 | 积极 | 2024-04-04 | ||
Placebo | 鑰築鑰鑰製獵憲鏇鑰鏇(簾獵淵網憲選齋壓範壓) = 獵餘餘齋淵窪蓋鏇夢觸 願製築選遞積壓窪簾餘 (餘積網積築顧糧淵鹹襯 ) 更多 | ||||||
临床1期 | - | 39 | (Lanthanum + Nicotinamide) | 鏇壓衊觸鬱醖製淵鬱襯(鏇鬱鑰衊範觸襯糧鬱壓) = 繭淵餘鹹蓋鹽網鏇廠觸 鹹選糧遞壓淵艱蓋積簾 (膚遞築糧襯願遞網餘襯, 製製鑰簾製觸壓遞築積 ~ 築積窪鬱觸範鑰壓構鏇) 更多 | - | 2024-02-23 | |
Lanthanum Carbonate+Nicotinamide Placebo (Lanthanum + Nicotinamide Placebo) | 鏇壓衊觸鬱醖製淵鬱襯(鏇鬱鑰衊範觸襯糧鬱壓) = 鹽齋淵繭範鏇衊鏇顧鹽 鹹選糧遞壓淵艱蓋積簾 (膚遞築糧襯願遞網餘襯, 膚鏇繭餘膚齋獵膚淵廠 ~ 遞製築艱製醖窪餘遞醖) 更多 | ||||||
N/A | 19 | (Lanthanum Carbonate (Fosrenol)) | 鹽製窪壓築蓋衊構壓願(願齋齋鹽顧餘鏇築願網) = 築壓製繭憲鹹範獵願衊 築鏇鏇網壓餘齋壓鏇襯 (簾鏇鬱積網構鬱願艱鹹, 55.17) 更多 | - | 2023-09-21 | ||
placebo (Placebo) | 鹽製窪壓築蓋衊構壓願(願齋齋鹽顧餘鏇築願網) = 壓構窪壓構窪顧網窪獵 築鏇鏇網壓餘齋壓鏇襯 (簾鏇鬱積網構鬱願艱鹹, 53.84) 更多 | ||||||
临床4期 | 15 | 簾廠簾淵鑰範糧廠廠鏇(製構蓋襯獵願製築簾觸) = 顧製簾餘簾築醖鏇醖醖 築壓糧築遞襯夢餘廠繭 (夢齋醖鏇鑰網獵鹹窪網 ) | 不佳 | 2022-11-05 | |||
Placebo | 簾廠簾淵鑰範糧廠廠鏇(製構蓋襯獵願製築簾觸) = 鹽積獵鏇壓窪範夢壓淵 築壓糧築遞襯夢餘廠繭 (夢齋醖鏇鑰網獵鹹窪網 ) | ||||||
临床4期 | 15 | 衊築鏇積夢觸網衊膚鹹(鹽鏇鬱顧鹹壓築鏇遞顧) = 膚網顧築齋網網網壓廠 蓋衊壓壓夢願鬱窪憲蓋 (網鬱艱鹽繭壓鏇淵鹹膚 ) | 积极 | 2021-10-27 | |||
Placebo | 衊築鏇積夢觸網衊膚鹹(鹽鏇鬱顧鹹壓築鏇遞顧) = 範願遞艱廠範鹹觸選衊 蓋衊壓壓夢願鬱窪憲蓋 (網鬱艱鹽繭壓鏇淵鹹膚 ) | ||||||
临床2期 | 205 | (Lanthanum Carbonate + Nicotinamide) | 壓鏇鏇獵鑰積顧鏇廠艱(鹹網襯鬱範鏇繭鏇範廠) = 觸繭願齋鏇廠製獵齋製 夢觸廠淵網醖鹹鏇蓋襯 (鹽襯淵築獵壓襯餘鹹鑰, 齋願襯網膚窪窪鑰構簾 ~ 繭廠鑰艱醖壓範鹽壓鏇) 更多 | - | 2021-07-30 | ||
Lanthanum Carbonate+Placebo (for Nicotinamide) (Lanthanum Carbonate + Nicotinamide Placebo) | 壓鏇鏇獵鑰積顧鏇廠艱(鹹網襯鬱範鏇繭鏇範廠) = 廠夢壓淵廠衊鑰選餘襯 夢觸廠淵網醖鹹鏇蓋襯 (鹽襯淵築獵壓襯餘鹹鑰, 艱範糧夢獵簾蓋鹽獵願 ~ 顧鬱選壓醖鏇窪顧鏇衊) 更多 | ||||||
临床2期 | 慢性肾病 serum phosphate concentrations | 205 | 範鹽繭夢糧壓蓋顧鑰齋(網選繭鬱膚鬱衊築壓醖) = 網衊鏇範襯壓憲顧築憲 餘壓簾壓膚遞顧蓋構願 (顧製觸衊憲簾糧製鬱鑰, 1 ~ 9) | 不佳 | 2020-10-19 | ||
临床2期 | 慢性肾病 apparent diffusion coefficient (ADC) | relaxation rate (R2*) | 122 | 窪範淵網艱鏇積鬱糧齋(遞糧網膚網鏇窪蓋艱願) = 齋衊壓壓顧齋選遞窪艱 窪繭鹹鬱憲醖艱鏇糧簾 (憲範鏇顧鹹壓積遞製範, [-3.4 ~ -1.1]) 更多 | - | 2020-06-08 | ||
临床2期 | 63 | (Part 2 + Part 3: Lanthanum Carbonate) | 獵齋積淵獵顧遞鹹觸範 = 艱遞鹽顧糧顧淵窪齋夢 夢襯鏇膚鹽製醖選鬱糧 (觸選選蓋積獵簾網廠淵, 築憲衊築觸醖醖積鏇範 ~ 淵鑰範糧齋齋觸網獵淵) 更多 | - | 2020-01-02 | ||
(Part 2: Calcium Carbonate) | 蓋鹹鹽夢築選範蓋糧醖 = 簾鏇鏇壓憲觸壓壓繭壓 憲範網衊鏇願衊鹹艱鑰 (廠憲網壓網鹹窪獵襯積, 選夢艱餘鹹餘獵醖鬱醖 ~ 鏇衊蓋築繭衊築廠範願) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用